Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of Aldafermin in Subjects With Primary Sclerosing Cholangitis (ALPINE-PSC).

NCT06654726 is registered in ClinicalTrials.gov with NGM Biopharmaceuticals, Inc as lead sponsor.

NCT NCT06654726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06654726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of Aldafermin in Subjects With Primary Sclerosing Cholangitis (ALPINE-PSC).
Lead sponsor
NGM Biopharmaceuticals, Inc
Phase
Phase 2/3
Overall status
Withdrawn
Start date
October 21, 2024
Completion date
March 18, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary sclerosing cholangitis